Histone deacetylases modulate resistance to the therapy in lung cancer

E Contreras-Sanzón, H Prado-Garcia… - Frontiers in …, 2022 - frontiersin.org
The acetylation status of histones located in both oncogenes and tumor suppressor genes
modulate cancer hallmarks. In lung cancer, changes in the acetylation status are associated …

Histone deacetylase inhibition in non-small cell lung cancer: hype or hope?

H Mamdani, SI Jalal - Frontiers in cell and developmental biology, 2020 - frontiersin.org
Epigenetic modulation, including acetylation, methylation, phosphorylation, and
ubiquitination, plays a pivotal role in regulation of gene expression. Histone acetylation—a …

Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer: where are we now and what should we expect?

C Damaskos, I Tomos, N Garmpis… - Anticancer …, 2018 - ar.iiarjournals.org
Non-small cell lung cancer constitutes the most common type of lung cancer, accounting for
85-90% of lung cancer, and is a leading cause of cancer-related death. Despite the progress …

Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?

V Petta, I Gkiozos, A Strimpakos, K Syrigos - Cancer chemotherapy and …, 2013 - Springer
Purpose Deoxyribonucleic acid is wrapped around an octamer of core histone proteins to
form a nucleosome, the basic structure of chromatin. Two main families of enzymes maintain …

Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer

SA Ganai, BA Shah, MA Yatoo - Advances in cancer research, 2023 - Elsevier
The back-breaking resistance mechanisms generated by lung cancer cells against
epidermal growth factor receptor (EGFR), KRAS and Janus kinase 2 (JAK2) directed …

[HTML][HTML] Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications

Z Li, WG Zhu - International journal of biological sciences, 2014 - ncbi.nlm.nih.gov
Genetic abnormalities have been conventionally considered as hallmarks of cancer.
However, studies over the past decades have demonstrated that epigenetic regulation also …

Histone deacetylase inhibitors: emerging anticancer therapeutic agents?

R Kristeleit, P Fong, GW Aherne, J de Bono - Clinical lung cancer, 2005 - Elsevier
Histone deacetylase inhibitors are novel anticancer agents in clinical development that
target the family of histone deacetylase (HDAC) enzymes responsible for deacetylating core …

[HTML][HTML] The role of histone deacetylases (HDACs) in human cancer

S Ropero, M Esteller - Molecular oncology, 2007 - Elsevier
The balance of histone acetylation and deacetylation is an epigenetic layer with a critical
role in the regulation of gene expression. Histone acetylation induced by histone acetyl …

Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy

M Ahmad, A Hamid, A Hussain, R Majeed… - DNA and cell …, 2012 - liebertpub.com
Cancer is a pathologic condition that involves genetic and epigenetic events culminating in
neoplastic transformation. Alteration in epigenetic events that regulate the transcriptional …

Characterization of histone deacetylase mechanisms in cancer development

R Hai, L He, G Shu, G Yin - Frontiers in Oncology, 2021 - frontiersin.org
Over decades of studies, accumulating evidence has suggested that epigenetic
dysregulation is a hallmark of tumours. Post-translational modifications of histones are …